Acotec Scientific Holdings (STU:7W3) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7W3 Acotec Scientific Holdings Ltd STU:7W3
76 GF Score
Price €0.67
GF Value €1.58
! 4 Warning Signs
View Full Analysis

What is Acotec Scientific Holdings FFO?

FFO (Funds from operations) only applies to REITs.

STU:7W3
76GF Score
Acotec Scientific Holdings Ltd STU:7W3
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Acotec Scientific Holdings (STU:7W3) Overvalued in 2026?

Based on GuruFocus' analysis, Acotec Scientific Holdings stock appears to be undervalued. The current stock price of €0.67 is trading 57.6% below its estimated GF Value™ of €1.58.

Key valuation signals for STU:7W3:

  • FFO:
  • GF Value™: €1.58 vs. price of €0.67 (57.6% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the STU:7W3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Acotec Scientific Holdings Business Description

Other Exchanges 06669:Hong Kong
Address 16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical technology company, focusing on the research and development, and application of technology platforms in the field of vascular interventional treatment. Its product portfolio comprises Semi-compliant PTCA balloon (YAN), Coronary CTO Recanalization Balloon (RT-Zero), Coronary CTO Antegrade Micro-Catheter (Vericor-14), Coronary High-Pressure Balloon (YIYAN), Coronary CTO Retrograde Micro-Catheter (Vericor-RS), Cardiac Valve Balloon Dilation Catheter (RunFlow), etc., and also has various other products in its development pipeline. Geographically, the company generates a majority of its revenue from Mainland China, and the rest from other regions. The firm generates the majority of its revenue from sales to Domestic distributors.
76GF Score

Get the complete analysis for STU:7W3

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.67
Price
€1.58
GF Value